$GNLX
GENELUX Corp Stock $gnlx

$gnlx Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000149315224045790 Filed on November 14, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development		$4.051M
YoY Change		43.7%
% of Gross Profit
Depreciation & Amortization		$56.00K
YoY Change		-58.21%
% of Gross Profit
Operating Expenses		$6.941M
YoY Change		30.79%
Operating Profit		-$6.941M
YoY Change		30.79%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net		$474.0K
YoY Change		-1347.37%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings		-$6.467M
YoY Change		20.99%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.19
Diluted Earnings Per Share		-$0.19
COMMON SHARES
Basic Shares Outstanding	34.54M shares	34.54M shares
Diluted Shares Outstanding		34.53M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$34.06M
YoY Change		14.02%
Cash & Equivalents		$6.102M
Short-Term Investments		$27.96M
Other Short-Term Assets		$1.910M
YoY Change		45.8%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets		$35.97M
YoY Change		15.36%
LONG-TERM ASSETS
Property, Plant & Equipment		$1.278M
YoY Change		25.05%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$1.003M
YoY Change
Other Assets		$92.00K
YoY Change		0.0%
Total Long-Term Assets		$4.303M
YoY Change		48.74%
TOTAL ASSETS
Total Short-Term Assets		$35.97M
Total Long-Term Assets		$4.303M
Total Assets		$40.27M
YoY Change		18.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$4.454M
YoY Change		11.1%
Accrued Expenses		$1.101M
YoY Change		-73.4%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change		-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$5.555M
YoY Change		-36.55%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change		-100.0%
Other Long-Term Liabilities		$1.624M
YoY Change		25.99%
Total Long-Term Liabilities		$1.624M
YoY Change		25.99%
TOTAL LIABILITIES
Total Short-Term Liabilities		$5.555M
Total Long-Term Liabilities		$1.624M
Total Liabilities		$7.179M
YoY Change		-28.52%
SHAREHOLDERS EQUITY
Retained Earnings		-$242.4M
YoY Change		12.88%
Common Stock		$35.00K
YoY Change		29.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$433.0K
YoY Change		0.0%
Treasury Stock Shares
Shareholders Equity		$33.09M
YoY Change
Total Liabilities & Shareholders Equity		$40.27M
YoY Change		18.19%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$6.467M
YoY Change		20.99%
Depreciation, Depletion And Amortization		$56.00K
YoY Change		-58.21%
Cash From Operating Activities		-$5.748M
YoY Change		71.33%
INVESTING ACTIVITIES
Capital Expenditures		$27.00K
YoY Change		-90.07%
Acquisitions
YoY Change
Other Investing Activities		$4.019M
YoY Change
Cash From Investing Activities		$3.992M
YoY Change		-1567.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		0.000
YoY Change		-100.0%
NET CHANGE
Cash From Operating Activities		-5.748M
Cash From Investing Activities		3.992M
Cash From Financing Activities		0.000
Net Change In Cash		-1.756M
YoY Change		-164.28%
FREE CASH FLOW
Cash From Operating Activities		-$5.748M
Capital Expenditures		$27.00K
Free Cash Flow		-$5.775M
YoY Change		59.22%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0583529
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2625 Townsgate Road
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 230
	dei	Entity Address City Or Town EntityAddressCityOrTown	Westlake Village
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91361
	dei	City Area Code CityAreaCode	(805)
	dei	Local Phone Number LocalPhoneNumber	267-9889
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	34538185	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6102000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9418000	usd
CY2024Q3	us-gaap	Short Term Investments ShortTermInvestments	27955000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	13773000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1910000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1012000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	35967000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	24203000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1278000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1170000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1930000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2428000	usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments		usd
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2024Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2023Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2024Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense		usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense		usd
CY2023Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments		usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments		usd
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Entity Registrant Name EntityRegistrantName	GENELUX CORPORATION
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity File Number EntityFileNumber	001-41599
	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.001
	dei	Trading Symbol TradingSymbol	GNLX
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q3	us-gaap	Long Term Investments LongTermInvestments	1003000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	92000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	92000	usd
CY2024Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	4303000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	3690000	usd
CY2024Q3	us-gaap	Assets Assets	40270000	usd
CY2023Q4	us-gaap	Assets Assets	27893000	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4454000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3784000	usd
CY2024Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	686000	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	2117000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	415000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	653000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5555000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6554000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1624000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1866000	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34538185	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34538185	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26788986	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26788986	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	35000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	27000	usd
CY2024Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	433333	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	433333	shares
CY2024Q3	us-gaap	Treasury Stock Value TreasuryStockValue	433000	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	433000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	241389000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	124000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	14000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-242417000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-221524000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	33091000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	19473000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40270000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27893000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	170000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4051000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2819000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12478000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8607000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2890000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2488000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9478000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8727000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	6941000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	5307000	usd
	us-gaap	Operating Expenses OperatingExpenses	21956000	usd
	us-gaap	Operating Expenses OperatingExpenses	17334000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6941000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5307000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21948000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17164000	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	474000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1055000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	649000	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	3152000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-402000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	474000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-38000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1055000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4366000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-5345000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-20893000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-21530000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.69
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.91
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.91
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34532355	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26210068	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26210068	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30405615	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30405615	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23640995	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23640995	shares
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-6467000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-5345000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-20893000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-21530000	usd
CY2024Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	135000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	110000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6332000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5345000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20783000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21530000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	37669000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1521000	usd
CY2024Q3	GNLX	Unrealized Gain On Shortterm Investments UnrealizedGainOnShorttermInvestments	135000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	227000	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001231457
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating		usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating		usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating		usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023Q3	GNLX	Conversion Of Notes Payable Shareholders And Accrued Interest ConversionOfNotesPayableShareholdersAndAccruedInterest		usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
	GNLX	Issuance Of Common Shares Upon Conversion Of Preferred Stock Dividends Payable IssuanceOfCommonSharesUponConversionOfPreferredStockDividendsPayable		usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments		usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	GNLX	Fair Value Of Warrants With Conversion Of Convertible Notes Payable FairValueOfWarrantsWithConversionOfConvertibleNotesPayable		usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet		usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments		usd
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments		usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
	GNLX	Payment Of Deferred Offering Costs PaymentOfDeferredOfferingCosts		usd
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	GNLX	Proceeds From Issuance Of Second Offering ProceedsFromIssuanceOfSecondOffering		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	GNLX	Extension Of Rightofuse Asset And Operating Lease ExtensionOfRightofuseAssetAndOperatingLease		usd
	GNLX	Reclassification Of Deferred Offering Costs To Shareholders Equity ReclassificationOfDeferredOfferingCostsToShareholdersEquity		usd
	GNLX	Reclassification Of Warrant Liabilities To Shareholders Equity ReclassificationOfWarrantLiabilitiesToShareholdersEquity		usd
	GNLX	Conversion Of Convertible Notes Payable Accrued Interest And Loan Fees To Shareholders Equity ConversionOfConvertibleNotesPayableAccruedInterestAndLoanFeesToShareholdersEquity		usd
	GNLX	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock		usd
	GNLX	Conversion Of Dividends Payable To Shareholders Equity ConversionOfDividendsPayableToShareholdersEquity		usd
	GNLX	Conversion Of Notes Payable Shareholders And Accrued Interest To Shareholders Equity ConversionOfNotesPayableShareholdersAndAccruedInterestToShareholdersEquity		usd
	GNLX	Unrealized Gain On Investments UnrealizedGainOnInvestments		usd
	GNLX	Accrual Of Other Receivable AccrualOfOtherReceivable		usd
	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss		usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodTotalFairValue		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	GNLX	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Exercised SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceExercised
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeited Exercise Price Range ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedExercisePriceRange
	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeited Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice
	dei	Document Type DocumentType	10-Q
CY2024Q3	us-gaap	Liabilities Liabilities	7179000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	8420000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	275782000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	4000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	4000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	167000	usd
CY2023Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	42000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-6467000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34532355	shares
CY2024Q3	GNLX	Adjustments To Additional Paid In Capital Cost Of Stock Option Modifications And Repricing AdjustmentsToAdditionalPaidInCapitalCostOfStockOptionModificationsAndRepricing	6000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-6467000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	33091000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	19473000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4308000	usd
	GNLX	Unrealized Gain On Shortterm Investments UnrealizedGainOnShorttermInvestments	110000	usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1352000	usd
	GNLX	Adjustments To Additional Paid In Capital Cost Of Stock Option Modifications And Repricing AdjustmentsToAdditionalPaidInCapitalCostOfStockOptionModificationsAndRepricing	326000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	27678000	usd
	GNLX	Stock Issued During Period Value Issuance Of Common Stock In Connection With Companys Equity Award Programs StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithCompanysEquityAwardPrograms	49000	usd
	GNLX	Stock Issued During Period Value Issuance Of Common Stock In Connection With Companys Equity Award Programs StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithCompanysEquityAwardPrograms	49000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	688000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-20893000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	33091000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	22256000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	515000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3500000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3500000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	147000	usd
CY2023Q3	GNLX	Adjustments To Additional Paid In Capital Cost Of Stock Option Modifications And Repricing AdjustmentsToAdditionalPaidInCapitalCostOfStockOptionModificationsAndRepricing	25000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	42000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	42000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1321000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	1567000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-5345000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	24028000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-35783000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-35783000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	982000	usd
	GNLX	Stock Issued During Period Value Issuance Of Common Shares Upon Closing Of Initial Public Offering Net Of Offering Costs StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponClosingOfInitialPublicOfferingNetOfOfferingCosts	12632000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	25142000	usd
	GNLX	Issuance Of Common Shares Upon Conversion Of Convertible Notes Payable Accrued Interest And Loan Fees IssuanceOfCommonSharesUponConversionOfConvertibleNotesPayableAccruedInterestAndLoanFees	29896000	usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	774000	usd
	GNLX	Adjustments To Additional Paid In Capital Cost Of Stock Option Modifications And Repricing AdjustmentsToAdditionalPaidInCapitalCostOfStockOptionModificationsAndRepricing	2667000	usd
	GNLX	Adjustments To Additional Paid In Capital Cost Of Stock Option Modifications And Repricing AdjustmentsToAdditionalPaidInCapitalCostOfStockOptionModificationsAndRepricing	2667000	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	169000	usd
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	3152000	usd
	GNLX	Conversion Of Notes Payable Shareholders And Accrued Interest ConversionOfNotesPayableShareholdersAndAccruedInterest	1865000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1321000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	2741000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-21530000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-21530000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	24028000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	24028000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-20893000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-21530000	usd
	us-gaap	Depreciation Depreciation	178000	usd
	us-gaap	Depreciation Depreciation	404000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	556000	usd
	GNLX	Rightofuse Asset RightofuseAsset	498000	usd
	GNLX	Rightofuse Asset RightofuseAsset	413000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	649000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4308000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	982000	usd
	GNLX	Fair Value Of Restricted Stock Units FairValueOfRestrictedStockUnits	1352000	usd
	GNLX	Fair Value Of Restricted Stock Units FairValueOfRestrictedStockUnits	774000	usd
	GNLX	Cost Of Stock Option Modifications Repricing CostOfStockOptionModificationsRepricing	-326000	usd
	GNLX	Cost Of Stock Option Modifications Repricing CostOfStockOptionModificationsRepricing	-2667000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-402000	usd
	GNLX	Fair Value Of Warrants With Conversion Of Convertible Notes Payable FairValueOfWarrantsWithConversionOfConvertibleNotesPayable	3152000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	568000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-185000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	340000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2133000	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	-1431000	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	1249000	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	22000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-170000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-480000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-431000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16926000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13365000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	285000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	782000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	28520000	usd
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	14000000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14805000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-782000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	900000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	685000	usd
	GNLX	Payment Of Deferred Offering Costs PaymentOfDeferredOfferingCosts	303000	usd
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	49000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1321000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	688000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2741000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	14503000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25142000	usd
	GNLX	Proceeds From Issuance Of Second Offering ProceedsFromIssuanceOfSecondOffering	27678000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28415000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	43619000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3316000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	29472000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9418000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	397000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6102000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29869000	usd
	us-gaap	Interest Paid Net InterestPaidNet	72000	usd
	GNLX	Extension Of Rightofuse Asset And Operating Lease ExtensionOfRightofuseAssetAndOperatingLease	845000	usd
	GNLX	Reclassification Of Deferred Offering Costs To Shareholders Equity ReclassificationOfDeferredOfferingCostsToShareholdersEquity	1871000	usd
	GNLX	Reclassification Of Warrant Liabilities To Shareholders Equity ReclassificationOfWarrantLiabilitiesToShareholdersEquity	169000	usd
	GNLX	Conversion Of Convertible Notes Payable Accrued Interest And Loan Fees To Shareholders Equity ConversionOfConvertibleNotesPayableAccruedInterestAndLoanFeesToShareholdersEquity	29896000	usd
	GNLX	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock	22000	usd
	GNLX	Conversion Of Dividends Payable To Shareholders Equity ConversionOfDividendsPayableToShareholdersEquity	3443000	usd
	GNLX	Conversion Of Notes Payable Shareholders And Accrued Interest To Shareholders Equity ConversionOfNotesPayableShareholdersAndAccruedInterestToShareholdersEquity	1463000	usd
	GNLX	Unrealized Gain On Investments UnrealizedGainOnInvestments	110000	usd
	GNLX	Accrual Of Other Receivable AccrualOfOtherReceivable	330000	usd
	us-gaap	Basis Of Accounting BasisOfAccounting	<p id="xdx_809_eus-gaap--BasisOfAccounting_zWdltGmLIvO3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE 1 – <span id="xdx_821_zcrtYb6nYJFl">BASIS OF PRESENTATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Organization and Operations</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genelux Corporation (“Genelux” or the “Company”), a Delaware Corporation, incorporated on September 4, 2001, is a late clinical-stage biopharmaceutical company located in Westlake Village, California. The Company is engaged in the research and development of diagnostic and therapeutic solutions for cancer for which there is no effective treatment today. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Basis of Presentation of Unaudited Financial Information</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity and Capital Resources</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2023, the Company incurred a net loss of $<span id="xdx_905_eus-gaap--NetIncomeLoss_iN_pn3n3_di_c20230101__20231231_zNtqFW5NGqgk" title="Net loss">28,297</span> and used cash in operations of $<span id="xdx_900_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20230101__20231231_z1HG8rerrgY8" title="Cash used in operations">20,275</span> and had an accumulated deficit of $<span id="xdx_901_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20231231_zXz7i1Et0lO7" title="Accumulated deficit">221,524</span> as of December 31, 2023. As reflected in the accompanying condensed financial statements, during the nine months ended September 30, 2024, the Company incurred a net loss of $<span id="xdx_90E_eus-gaap--NetIncomeLoss_iN_pn3n3_di_c20240101__20240930_zb2uv87PN434" title="Net loss">20,893</span> and used cash in operations of $<span id="xdx_904_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20240101__20240930_zXkHuYQM6Kw2" title="Cash used in operations">16,926</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">During the year ended December 31, 2023, the Company closed its initial public offering (“IPO”) and two private placements and received $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zXPLOx9xwD44" title="Proceeds from issuance of private placement">37,774</span> of net proceeds from these offerings. During the nine months ended September 30, 2024, the Company closed its second public offering and received $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20240101__20240930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zDOQYQVzJkj" title="Proceeds from issuance of private placement">27,678</span> of net proceeds from that offering (see Note 8). Due to the funds received through these offerings, and the conversion of preferred stock and convertible notes payable upon the closing of the IPO, the Company had shareholders’ equity of $<span id="xdx_900_eus-gaap--StockholdersEquity_iI_pn3n3_c20240930_zRw8RiA7fWC1" title="Shareholders equity">33,091</span> at September 30, 2024. The Company now expects its cash and cash equivalents, and short and long-term investments, totaling $<span id="xdx_901_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn3n3_c20240930_z9fF3UtFRxMg" title="Cash cash equivalents short-term investments">35,060</span> at September 30, 2024, to last into the first quarter of 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. Since inception, the Company has funded its operations primarily through equity and debt financings, and licensing income, and it expects to continue to rely on these sources of capital in the future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our stockholders, in case of equity financing, or grant unfavorable terms in future licensing agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-28297000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20275000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-221524000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-20893000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16926000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	33091000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	35060000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_ztNRERRoQAwb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accruals for potential liabilities, valuations of stock-based compensation, and realization of deferred tax assets, among others. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12973241	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5844308	shares
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	110000	usd
CY2024Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	34465000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	28837000	usd
	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain	121000	usd
CY2024Q3	us-gaap	Debt Securities Trading And Available For Sale DebtSecuritiesTradingAndAvailableForSale	28958000	usd
CY2024Q3	us-gaap	Short Term Investments ShortTermInvestments	27955000	usd
CY2024Q3	us-gaap	Long Term Investments LongTermInvestments	1003000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4905000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4619000	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3627000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3449000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1278000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1170000	usd
	us-gaap	Depreciation Depreciation	178000	usd
	us-gaap	Depreciation Depreciation	404000	usd
CY2023Q4	GNLX	Facility Design Services FacilityDesignServices	995000	usd
	GNLX	Additional Design Services AdditionalDesignServices	241000	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	2117000	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current And Noncurrent AccruedPayrollTaxesCurrentAndNoncurrent	321000	usd
CY2024Q3	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	1259000	usd
CY2024Q3	us-gaap	Accrued Payroll Taxes Current And Noncurrent AccruedPayrollTaxesCurrentAndNoncurrent	321000	usd
CY2024Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	686000	usd
	us-gaap	Payments For Rent PaymentsForRent	66000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	498000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	413000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1930000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2428000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2519000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	480000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	431000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2039000	usd
	GNLX	Rent Expense RentExpense	27000	usd
	GNLX	Rent Expense RentExpense	27000	usd
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34538185	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34538185	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26788986	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26788986	shares
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	0	usd
	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	25142000	usd
CY2024Q2	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	30000000	usd
CY2024Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	27678000	usd
CY2024Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.25
CY2024Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	57900	shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested	1297000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	22.40
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	311684	shares
	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue	1212000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.89
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	156810	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	1114000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	7.11
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	212774	shares
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested	1395000	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	6.56
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1352000	usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	774000	usd
CY2024Q3	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	1395000	usd
	GNLX	Fair Market Value Of Shares Percentage Description FairMarketValueOfSharesPercentageDescription	(i) 100% of the fair market value of a share of stock on the grant date, or (ii) 110% of the fair market value of a share of stock on the grant date in the case of a Participant then owning more than 10% of the total combined voting power of all classes of stock of the Company or any “subsidiary corporation” of the Company or any “parent corporation” of the Company.
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.039	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.045	pure
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5118920	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.76
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	233376	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.35
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	80471	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	14.15
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	409333	shares
	GNLX	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Expired SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceExpired	6.00
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	6.34
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4862492	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.47
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	3776072	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	7.38
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1086420	shares
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	17.42
	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit	6.00
	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit	24.75
CY2024Q3	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	4862492	shares
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P5Y4M24D
CY2024Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	9.47
CY2024Q3	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	3776072	shares
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P4Y4M6D
CY2024Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	7.38
	GNLX	Cost Of Stock Option Modifications CostOfStockOptionModifications	-303000	usd
CY2022Q3	GNLX	Repricing Costs RepricingCosts	2733000	usd
CY2023	GNLX	Repricing Costs RepricingCosts	2689000	usd
	us-gaap	Stock Granted During Period Value Sharebased Compensation Forfeited StockGrantedDuringPeriodValueSharebasedCompensationForfeited	23000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4308000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	982000	usd
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	83000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	512759	shares
CY2023Q4	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	7.14
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	7500000	shares
CY2024Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	5.25
	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Issued Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice	5.25
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	76487	shares
	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Exercise Price Range ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedExercisePriceRange	9.00
	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice	9.00
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	38297	shares
	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expired Exercise Price Range ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredExercisePriceRange	10.50
	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expired Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice	10.50
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	7897975	shares
CY2024Q3	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	5.32
CY2024Q3	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	7897975	shares
CY2024Q3	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	5.32
	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	3.00
	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	9.00
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	7897975	shares
	GNLX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm	P4Y6M18D
CY2024Q3	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	5.32
CY2024Q3	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	7897975	shares
	GNLX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercisable Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm	P4Y6M18D
CY2024Q3	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	5.32
CY2023Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	430086	shares
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2741000	usd
CY2024Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	7500000	shares
CY2024Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.25
CY2024Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2024Q3	GNLX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue	0	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	49000	usd

Files In Submission

Name	View Source	Status
0001493152-24-045790-index-headers.html	Edgar Link	pending
0001493152-24-045790-index.html	Edgar Link	pending
0001493152-24-045790.txt	Edgar Link	pending
0001493152-24-045790-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
gnlx-20240930.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
gnlx-20240930_cal.xml	Edgar Link	unprocessable
gnlx-20240930_def.xml	Edgar Link	unprocessable
gnlx-20240930_lab.xml	Edgar Link	unprocessable
gnlx-20240930_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GNLX
GENELUX Corp Stock $gnlx

2024 Q4 Form 10-Q Financial Statement

#000149315224045790 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GNLX GENELUX Corp Stock $gnlx

2024 Q4 Form 10-Q Financial Statement

#000149315224045790 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GNLX
GENELUX Corp Stock $gnlx